Table 1.

Summary data for subjects from whom C. difficile was isolated and classification of isolates regarding ribotype and the presence of a pathogenicity locus

Subject	Sex	Age (yr)	Ribotype	Stratificationa	Antibiotic usage within 4 weeks prior to sampling	tcdA/tcdB
EM011	F	86	027	D	No antibiotic usage recorded	+/+
EM012	F	85	002	D	Unknown	+/+
EM045	M	67	072	D	No antibiotic usage recorded	+/+
EM069	M	83	072	R	No antibiotic usage recorded	+/+
EM112	F	84	027	LS	Amoxicillin, tazocin, flagyl, ciprofloxacin	+/+
EM113	M	75	072	R	Penicillin, moxifloxacin	+/+
EM124	M	79	072	LS	Ciproxin, augmentin	+/+
EM126	M	75	072	LS	No antibiotic usage recorded	+/+
EM136	M	73	014	LS	No antibiotic usage recorded	+/+
EM139	F	69	072	LS	No antibiotic usage recorded	+/+
EM140	F	78	072	LS	No antibiotic usage recorded	+/+
EM146	F	88	308	LS	No antibiotic usage recorded	+/+
EM148	M	71	072	R	No antibiotic usage recorded	+/+
EM149	F	82	010	C	Flucloxacillin	–/–
EM152	F	87	050	R	No antibiotic usage recorded	+/+
EM156	M	74	220	LS	No antibiotic usage recorded	+/+
EM186	F	87	308	LS	Trimethoprim, augmentin	+/+
EM188	F	96	018	LS	Augmentin	+/+
EM218	F	90	072	LS	Cephradine, co-amoxiclav	+/+
EM243	F	81	072	LS	No antibiotic usage recorded	+/+
EM255	F	91	072	LS	Augmentin	+/+
EM304	F	77	027	R	Klacid, clindamycin, flucoxacillin, penicillin, metronidazole, trimethoprim, ciprofloxacin, vancomycin, co-amoxiclav, tazocin	+/+
EM306	F	87	027	R	Vancomycin, flagyl	+/+
EM308	M	82	078	R	No antibiotics	+/+
EM321	F	84	026	R	No antibiotics	–/–
EM324	F	81	216	R	Co-amoxiclav	+/+
EM334	M	83	216	R	No antibiotics	+/+
EM336	F	70	216	C	Clarithromycin, co-amoxiclav	+/+

^aD, subjects in hospital as day patients; R, subjects in rehabilitation, i.e., less than 6 weeks as an in-patient; LS, long stay,i.e., subjects more than 6 weeks as an in-patient; C, community-dwelling subjects.